Mark Zuckerberg and wife Dr. Priscilla Chan recently announced a $3 billion initiative geared towards curing most of the world’s diseases called the Biohub. Through the Chan Zuckerberg Initiative, the couple managed to draw support from other billionaires and ordinary people alike in terms of funding and cooperation. Recently, the Facebook founder released a post detailing how a meeting with top scientists gave him hope that most, if not all of the world’s diseases will be gone by 2115.
The scientists in question are at the top of their fields with regards to dealing with illnesses and they come from multiple origins, including Stanford University and UC Berkeley. Heading the team is Dr. Cori Bargmann, who is a Rockefeller neuroscientist, Futurism reports.
Even with excellent brains behind the operation, the goal of eradicating even just a majority of the known diseases plaguing the world is a monumental undertaking. Much of the challenges has to do with research, which is a costly and time-consuming affair. The Biohub will take on a lot of the weight of the problems that usually prevent scientists from making swift progress, but even then, many would consider the 100-year timeline to be overly ambitious.
Zuckerberg and the team of scientists don’t seem to think so, however, and they point to the advancements that humanity has achieved in the last few decades in extending human lifespan. Global Futurist also notes how the initiative has already addressed one of the hurdles of getting to the point that they are aiming for; coordination.
There’s also the matter of the most recent innovations in medical and bioresearch to consider, which gives the lofty goals of a disease-free world a boost. There’s the new gene-editing tool called CRISPR, which is basically a starter kit for playing God. Then there’s the project called Cell Atlas, which aims to map all of the human body’s cells to address diseases that begin at the cellular level.


Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 



